A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To characterize the pharmacodynamic profile of 2 treatment courses of alemtuzumab
administered by subcutaneous injection and 2 treatment courses of alemtuzumab
administered by intravenous infusion in patients with progressive multiple sclerosis.
Secondary Objectives:
- To characterize the pharmacokinetic profiles of alemtuzumab administered by subcutaneous
injection or intravenous infusion to patients with progressive multiple sclerosis.
- To characterize the safety and tolerability of alemtuzumab administered by subcutaneous
injection or intravenous infusion to patients with progressive multiple sclerosis.